A review of contusugene ladenovec (Advexin) p53 therapy

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 1, 2009, Pages 54-61

  Senzer, N ^a   Nemunaitis, J ^a  

^a Mary Crowley Cancer Research Centers   (United States)

Author keywords

Ad p53; Adenovirus; Advexin; Gene therapy; p53

Indexed keywords

ADVEXIN; BIOLOGICAL MARKER; BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; PROTEIN P53; TAMOXIFEN; TUMOR ANTIGEN; VINBLASTINE;

ASTHENIA; BREAST CANCER; BYSTANDER EFFECT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL EVALUATION; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEVER; GENE DELETION; GENE MUTATION; GLIOMA; GRANULOSA CELL TUMOR; HEAD AND NECK CANCER; HEADACHE; HUMAN; INJECTION SITE PAIN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NAUSEA; NONHUMAN; PROSTATE CANCER; REVIEW; SQUAMOUS CELL CARCINOMA;

GENE THERAPY; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; VIRAL VACCINES;

ADENOVIRIDAE;

EID: 58849117646     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA: High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther (1994) 1(1):5-13.
2. Levine AJ, Hu W, Feng Z: The p53 pathway: What questions remain to be explored? Cell Death Diff (2006) 13(6):1027-1036.
3. Ding HF, Lin Y-L, McGill G, Juo P, Zhu H, Blenis J, Yuan J, Fisher DE: Essential role for caspase-8 in transcription-independent apoptosis triggered by p53. J Biol Chem (2000) 275(49):38905-38911.
4. Moll UM, Wolff S, Speidel D, Deppert W: Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol (2005) 17(6):631-636.
5. Vousden KH, Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol (2007) 8(4):275-283.
6. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J et al: A global map of p53 transcription-factor binding sites in the human genome. Cell (2006) 124(1):207-219.
7. Prives C, Hall PA: The p53 pathway. J Pathol (1999) 187(1):112-126.
8. Khwaja FW, Svoboda P, Reed M, Pohl J, Pyrzynska B, Van Meir EG: Proteomic identification of the wt-p53-regulated tumor cell secretome. Oncogene (2006) 25(58):7650-7661.
9. Lane DP: Cancer. p53, guardian of the genome. Nature (1992) 358(6381):15-16.
10. Yoo J, Lee HK, Kang CS, Park WS, Lee JY, Shim SI: p53 gene mutations and p53 protein expression in human soft tissue sarcomas. Arch Pathol Lab Med (1997) 121(4):395-399.
11. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M: TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene (2007) 26(15):2157-2165. • An informative overview of p53 mutant forms and distribution is provided in this paper.
12. Bourdon JC: p53 and its isoforms in cancer. Br J Cancer (2007) 97(3):277-282.
13. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP: p53 isoforms can regulate p53 transcriptional activity. Genes Dev (2005) 19(18):2122-2137. • An excellent review of the structure and function of p53 isoforms.
14. Boldrup L, Bourdon JC, Coates PJ, Sjostrom B, Nylander K: Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer (2007) 43(3):617-623.
15. Liu WL, Midgley C, Stephen C, Saville M, Lane DP: Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein. J Mol Biol (2001) 313(4):711-731.
16. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T: Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 445(7128):661-665. • An important paper that provides a rationale for restorative p53 gene therapy.
17. Martins CP, Brown-Swigart L, Evan GI: Modeling the therapeutic efficacy of p53 restoration in tumors. Cell (2006) 127(7):1323-1334. •• This study established the role of p53 in tumor maintenance, thereby supporting the concept of p53 restorative therapy.
18. ARF protein expression is a predictor of both relapse and survival in squamous cell carcinoma of the anterior tongue. Clin Cancer Res (2005) 11(11):4107-4116.
19. Sewell DA, Li D, Duan L, Schwartz MR, O'Malley BW Jr: Optimizing suicide gene therapy for head and neck cancer. Laryngoscope (1997) 107(11 Pt 1):1490-1495.
20. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 275(5304):1320-1333.
21. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP, Wang Z, Hsieh JT: Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res (1999) 59(2):325-330.
22. Tango Y, Taki M, Shirakiya Y, Ohtani S, Tokunaga N, Tsunemitsu Y, Kagawa S, Tani T, Tanaka N, Fujiwara T: Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of Coxsackie-adenovirus receptors in human lung cancer cells. Cancer Sci (2004) 95(5):459-463.
23. Frank DK, Frederick MJ, Liu TJ, Clayman GL: Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. Clin Cancer Res (1998) 4(10):2521-2528.
24. Waku T, Fujiwara T, Shao J, Itoshima T, Murakami T, Kataoka M, Gomi S, Roth JA, Tanaka N: Contribution of CD95 ligand-induced neutrophil infiltration to the bystander effect in p53 gene therapy for human cancer. J Immunol (2000) 165(10): 5884-5890.
25. Nishizaki M, Fujiwara T, Tanida T, Hizuta A, Nishimori H, Tokino T, Nakamura Y, Bouvet M, Roth JA, Tanaka N: Recombinant adenovirus expressing wild-type p53 is antiangiogenic: A proposed mechanism for bystander effect. Clin Cancer Res (1999) 5(5):1015-1023.
26. Harada H, Nakagawa K, Saito M, Kohno S, Nagato S, Furukawa K, Kumon Y, Hamada K, Ohnishi T: Introduction of wild-type p53 enhances thrombospondin-1 expression in human glioma cells. Cancer Lett (2003) 191(1):109-119.
27. Dreiling LK, Mohanty S, Merritt J, Proksch S, Shu C, Tomko L: Tolerance and safety of RPR/INGN 201, an adeno-viral vector containing a p53 gene, administered intratumorally in 309 patients with advanced cancer enrolled in phase I and II studies world-wide. Proc Am Soc Clin Oncol (1999) 19:Abs 460a.
28. Yver A, Gautier E, Saulnier P, Al E: Clinical biosafety, distribution, genetic stability and potential for transmission of adenoviral vector with RPR/INGN 201 (Ad5CMV-p53). Proc Am Soc Clin Oncol (2001) 20:Abs 1046.
29. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK et al: Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst (1999) 91(9):763-771. • A study of monomodal p53 restorative therapy in patients with NSCLC.
30. Fujiwara T, Tanaka N, Kanazawa S, Ohtani S, Saijo Y, Nukiwa T, Yoshimura K, Sato T, Eto Y, Chada S, Nakamura H et al: Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol (2006) 24(11):1689-1699.
31. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE et al: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res (2003) 9(1):93-101. • The combined treatment modality of p53 and radiation therapy was investigated in patients with NSCLC.
32. Tolcher AW, Hao D, de Bono J, Miller A, Patnaik A, Hammond LA, Smetzer L, Van Wart Hood J, Merritt J, Rowinsky EK, Takimoto C et al: Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. J Clin Oncol (2006) 24(13):2052-2058.
33. Gabrilovich DI: INGN 201 (Advexin): Adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther (2006) 6(8):823-832.
34. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy - Introgen, RPR/INGN 201. Drugs R&D (2007) 8(3):176-187.
35. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F et al: Adenovirus- mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol (2000) 18(3):609-622. • The combined treatment modality of p53 and chemotherapy (cisplatin) in patients with NSCLC was assessed in this clinical trial.
36. Soussi T: p53 Antibodies in the sera of patients with various types of cancer: A review. Cancer Res (2000) 60(7):1777-1788.
37. Shimada H, Ochiai T, Nomura F: Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: A multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer (2003) 97(3):682-689.
38. Li FP, Fraumeni JF Jr: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med (1969) 71(4):747-752.
39. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 250(4985):1233-1238.
40. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP: Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst (1998) 90(8):606-611.
41. Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, Evans DG, Birch JM: Germ-line mutations of TP53 in Li-Fraumeni families: An extended study of 39 families. Cancer Res (1997) 57(15):3245-3252.
42. Senzer N, Nemunaitis J, Nemunaitis M, Lamont J, Gore M, Gabra H, Eeles R, Sodha N, Lynch FJ, Zumstein LA, Menander KB et al: p53 Therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Ther (2007) 6(5):1478-1482. • The only published study of restorative p53 gene therapy for malignancy in a patient with a germline, rather than a sporadic, p53 mutation.
43. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W et al: TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 357(25):2552-2561.
44. Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L, Roth JA et al: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol (1998) 16(6):2221-2232.
45. Chan WM, Siu WY, Lau A, Poon RY: How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol (2004) 24(8):3536-3551. • An excellent discussion of the mechanism of action of p53 mutation with regard to p53 inactivation.
46. Valentin-Vega YA, Barboza JA, Chau GP, El-Naggar AK, Lozano G: High levels of the p53 inhibitor MDM4 in head and neck squamous carcinoma. Hum Pathol (2007) 38(10):1553-1562.
47. Zambetti GP, Levine AP: A comparison of the biological activities of wild-type and mutant p53. FASEB J (1993) 7(10):855-865.
48. Lane DP: Exploiting the p53 pathway for the diagnosis and therapy of human cancer. Cold Spring Harb Symp Quant Biol (2005) 70:489-497.
49. de Vries A, Flores ER, Miranda B, Hsieh HM, van Oostrom CT, Sage J, Jacks T: Targeted point mutations of p53 leads to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA (2002) 99(5):2948-2953.
50. McLure KG, Lee PW: How p53 binds DNA as a tetramer. EMBO J (1998) 17(12):3342-3350.
51. Lukashchuk N, Vousden KH: Ubiquitination and degradation of mutant p53. Mol Cell Biol 27(23):8284-8295.
52. Blandino G, Levine AJ, Oren M: Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene (1999) 18(2):477-485.
53. Koonin EV, Rogozin IB, Glazko GV: p53 gain-of-function: Tumor biology and bioinformatics come together. Cell Cycle (2005) 4(5):686-688.